UBS Group’s Sanofi Contingent Value Rights GCVRZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-91,084
| Closed | -$78K | – | 8942 |
|
|
2019
Q4 | $78K | Buy |
91,084
+39,500
| +77% | +$30.3K | ﹤0.01% | 6123 |
|
|
2019
Q3 | $29K | Sell |
51,584
-26,013
| -34% | -$14K | ﹤0.01% | 6523 |
|
|
2019
Q2 | $40K | Buy |
77,597
+9,272
| +14% | +$4.63K | ﹤0.01% | 6111 |
|
|
2019
Q1 | $31K | Sell |
68,325
-4,706
| -6% | -$2.2K | ﹤0.01% | 5933 |
|
|
2018
Q4 | $35K | Buy |
73,031
+4,659
| +7% | +$2.31K | ﹤0.01% | 6377 |
|
|
2018
Q3 | $36K | Buy |
68,372
+5,776
| +9% | +$3.1K | ﹤0.01% | 6423 |
|
|
2018
Q2 | $31K | Sell |
62,596
-16,082
| -20% | -$7.49K | ﹤0.01% | 6371 |
|
|
2018
Q1 | $33K | Sell |
78,678
-13,619
| -15% | -$5.48K | ﹤0.01% | 6035 |
|
|
2017
Q4 | $35K | Buy |
92,297
+6,665
| +8% | +$2.53K | ﹤0.01% | 6135 |
|
|
2017
Q3 | $31K | Sell |
85,632
-21,732
| -20% | -$8.05K | ﹤0.01% | 6154 |
|
|
2017
Q2 | $41K | Sell |
107,364
-2,468
| -2% | -$1.01K | ﹤0.01% | 5814 |
|
|
2017
Q1 | $49K | Buy |
109,832
+961
| +0.9% | +$422 | ﹤0.01% | 5546 |
|
|
2016
Q4 | $41K | Sell |
108,871
-20,577
| -16% | -$6.96K | ﹤0.01% | 5992 |
|
|
2016
Q3 | $35K | Buy |
129,448
+8,300
| +7% | +$2.1K | ﹤0.01% | 5811 |
|
|
2016
Q2 | $29K | Sell |
121,148
-28,022
| -19% | -$4.82K | ﹤0.01% | 5989 |
|
|
2016
Q1 | $17K | Sell |
149,170
-23,158
| -13% | -$2.51K | ﹤0.01% | 6343 |
|
|
2015
Q4 | $19K | Buy |
172,328
+37,965
| +28% | +$5.36K | ﹤0.01% | 6847 |
|
|
2015
Q3 | $25K | Buy |
134,363
+7,518
| +6% | +$2.56K | ﹤0.01% | 6507 |
|
|
2015
Q2 | $89K | Buy |
126,845
+33,044
| +35% | +$22.9K | ﹤0.01% | 5505 |
|
|
2015
Q1 | $64K | Buy |
93,801
+8,613
| +10% | +$6.02K | ﹤0.01% | 5828 |
|
|
2014
Q4 | $67K | Buy |
+85,188
| New | +$58.2K | ﹤0.01% | 6135 |
|
UBS Group's GCVRZ Position: Q1 2020 in Review
UBS Group sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 91,084 shares — an estimated $78K sold.
UBS Group first reported a position in GCVRZ in Q4 2014 and held it in 21 quarters. The position peaked at $89K in Q2 2015. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.
- UBS Group reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
- UBS Group sold 91,084 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $78K.
- UBS Group first reported a position in Sanofi Contingent Value Rights in Q4 2014 and held it in 21 quarters.
- UBS Group's Sanofi Contingent Value Rights position peaked at $89K in Q2 2015.
- 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.
Based on UBS Group's 13F filing for Q1 2020, filed 1 May 2020.